RecruitingPhase 2NCT07221500
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Sponsor: Nurix Therapeutics, Inc.
Cincinnati, OH · Cleveland, OH · Columbus, OH · +24 more sites